Comparative Pharmacology
Head-to-head clinical analysis: LACOSAMIDE versus TRILEPTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACOSAMIDE versus TRILEPTAL.
LACOSAMIDE vs TRILEPTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
Trileptal (oxcarbazepine) stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting repetitive firing of action potentials. It also modulates high-voltage-activated calcium channels and increases potassium conductance.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
Adults: 600 mg orally twice daily initially; titrate by 600 mg/day every week. Maintenance: 600-1200 mg twice daily.
None Documented
None Documented
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Parent oxcarbazepine: 1.3–2.3 hours; active metabolite MHD: 8–11 hours (monohydroxy derivative); clinically, the long MHD half-life supports twice-daily dosing.
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Renal excretion is the primary route; 95% of the dose is excreted in urine (79% as MHD, 20% as MHD conjugates, <1% as unchanged oxcarbazepine), and 4% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."